A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)

Condition:   Head and Neck Squamous Cell Carcinoma
Interventions:   Drug: AZD6738;   Drug: Olaparib
Sponsor:   AstraZeneca
Not yet recruiting - verified January 2017

http://ift.tt/2jsp1G1